Background: Severe side effects such as cardiotoxicity and leukemia limit long-term use of mitoxantrone (MTX) despite its recommendation in patients with malignant forms of relapsing remitting (RR) and secondary progressive (SP) multiple sclerosis (MS). Methods: We analyzed data on tolerability, measured as compliance with the treatment, and patients’ acceptance of an alternative MTX treatment schedule in 12 patients with aggressive RRMS or SPMS treated for at least 3 years with low/delayed dose MTX. Results: Twelve patients received 9–17 cycles of MTX treatment, with individual median doses of 7.6–12.16 mg/m2/course during 36 to 114 (median 49.5) months resulting in cumulative doses of 101.9–143.0 mg/m2 per patient. The overall follow-up period was 37–122 (median 69.5) months. Treatment was well tolerated and appreciated by patients according to the Treatment Satisfaction-Visual Analogue Scale. No significant safety findings were seen concerning cardiological, hematological and oncological follow-up. The patients showed a stabilization of disease progression and a reduced annual relapse rate. Conclusions: Delayed, and/or dose-reduced, long-term MTX regimens over several years might represent a feasible alternative treatment for MS patients without any other therapeutic options.

Keywords:
Multiple sclerosis, Mitoxantrone
1.
Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:1332–1338.
2.
Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, Gonsette RE, Butine MD, Goodkin DE: Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909–913.
3.
Pascual AM, Tellez N, Bosca I, Mallada J, Belenguer A, Abellan I, Sempere AP, Fernandez P, Magraner MJ, Coret F, Sanz MA, Montalban X, Casanova B: Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler 2009;15:1303–1310.
4.
Cocco E, Sardu C, Gallo P, Capra R, Amato MP, Trojano M, Uccelli A, Marrosu MG: Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008;14:1225–1233.
5.
Ellis R, Boggild M: Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009;15:505–850.
6.
Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, Tremlett H: Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010;74:1822–1826.
7.
Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW: Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple scerosis. Neurology 2010;74:1463–1470.
8.
Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE, Eisenmann S, Le Page, E, Butine MD, De Goodkin DE: A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441–445.
9.
Zingler VC, Strupp M, Jahn K, Gross A, Hohlfeld R, Brandt T: The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis: an applied study in 65 patients. Nervenarzt 2005;76:740–747.
10.
Gonsette R, Demontly L: Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990;40:261.
11.
Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H: Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992;242:96–102.
12.
Noseworthy JH, Hopkins MB, Vandervoort MK, et al: An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993;43:1401–1406.
13.
Bastianello S, Pozzilli C, D’Andrea F, et al: A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994;21:266–270.
14.
Millefiorini E, Gasperini C, Pozzilli C, D’Andrea F, Bastianello S, Trojano M, Morino S, Morra VB, Bozzao A, Calo A, Bernini ML, Gambi D, Prencipe M: Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24- month clinical and MRI outcome. J Neurol 1997;244:153–159.
15.
Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraud O: Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112–118.
16.
Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018–2025.
17.
Cohen A, Mikol D: Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004;63(suppl 6):S28–S32.
18.
Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G: Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008;79:52–56.
19.
Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Vollmer T: Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol 2008;255:1473–1478.
20.
Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL: Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008;14:663–670.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.